Male Enhancement Filler Material Safety Data: HA vs. PLA vs. PMMA Compared

In 2024, dermal filler procedures ranked as the second most popular minimally invasive cosmetic treatment in the United States, with over 6.26 million procedures performed. Yet despite this volume, the specific safety data for penile girth enhancement (PGE) fillers remains poorly understood by most patients—including the high-income professionals who represent the fastest-growing demographic seeking these procedures.

The core problem is straightforward: no FDA-approved filler exists specifically for penile girth enhancement. Every material used is either FDA-approved for other indications and used off-label, or entirely unapproved and illegal. This distinction represents the most important safety divide a patient must understand before considering any procedure.

This article presents the Reversibility Spectrum as an organizing framework for evaluating filler safety: fully reversible (hyaluronic acid) → semi-permanent (polylactic acid) → permanent (PMMA) → unapproved/illegal (liquid silicone, paraffin, oils). Reversibility serves as a clinically meaningful proxy for safety because it determines whether complications—when they occur—can be corrected.

The purpose here is to provide the same evidence-based comparative safety framework a urologist would use, grounded in 2024 American Urological Association (AUA) data, peer-reviewed meta-analyses, and regulatory guidance from the FDA, Sexual Medicine Society of North America (SMSNA), and British Association of Urological Surgeons (BAUS).

Why Material Choice Is the Most Important Safety Variable in Penile Girth Enhancement

The filler material itself—not just technique—determines the nature, severity, and reversibility of potential complications. Understanding this principle is essential for any man evaluating this procedure.

The off-label reality must be stated clearly: hyaluronic acid (HA) was FDA-approved as a dermal filler in 2003 for facial and hand use. Polylactic acid (PLA) and PMMA (marketed as Bellafill®) carry their own FDA approvals for non-penile indications. None are FDA-approved specifically for penile girth enhancement.

Two critical regulatory tiers exist: (1) FDA-approved materials used off-label, and (2) completely unapproved or illegal substances. The AUA’s position statement, reaffirmed in 2018, establishes that subcutaneous fat injection for penile girth is “not shown to be safe or efficacious”—setting a baseline for what the evidence does and does not support.

The 2024 SMSNA position statement adds another critical requirement: penile dysmorphic disorder (body dysmorphic disorder focused on genitalia) must be formally ruled out before any invasive penile enhancement procedure. This psychological screening step is almost entirely absent from non-specialist providers—a significant red flag for patient safety.

For interpreting the adverse event data that follows, the Clavien-Dindo grading system provides context: Grade 1–2 complications are minor and manageable, while Grade 3–5 complications are serious and potentially life-altering.

The Reversibility Spectrum: A Clinical Safety Framework

Reversibility represents the most clinically meaningful safety axis because it answers a critical question: if a complication occurs, can it be corrected?

The Four-Tier Spectrum:

• Tier 1 — Fully Reversible: Hyaluronic acid, dissolvable with hyaluronidase enzyme
• Tier 2 — Semi-Permanent: Polylactic acid, biostimulator, not reversible
• Tier 3 — Permanent: PMMA, non-resorbable microspheres, not reversible
• Tier 4 — Unapproved/Illegal: Liquid silicone, paraffin, oils—permanent, migrating, catastrophic

Moving right on this spectrum means exponentially higher stakes if something goes wrong. The 2026 BAUS consensus document, covering 36 studies with 3,748 patients, and the 2024 SMSNA position statement both implicitly endorse this framework by recommending the least-permanent, most-reversible options as first-line approaches.

A critical clarification: “permanent” does not mean “better results.” It means permanent consequences—including permanent complications.

Hyaluronic Acid (HA) Filler: Safety Profile of the Fully Reversible Option

Hyaluronic acid occupies Tier 1 on the reversibility spectrum—the only PGE filler material where complications can be pharmacologically reversed using hyaluronidase enzyme. HA represents approximately 78% of all injectable dermal fillings globally, making it the most extensively studied filler material in existence.

While FDA-approved for facial and hand use since 2003, HA’s use for PGE remains off-label in the United States. However, the Korean Ministry of Food and Drug Safety has approved specific HA fillers for penile girth enhancement, providing international regulatory precedent.

2024 AUA Data: Adverse Event Rates for HA in Penile Girth Enhancement

The landmark retrospective safety study of nearly 500 men receiving HA filler for PGE, presented at the 2024 AUA Annual Meeting, delivered compelling safety data: all complications were Clavien-Dindo Grade 1–2 (minor only).

Specific rates from the AUA 2024 data:

• Infection rate: 0.42%
• Granuloma rate: 0.63%
• Erectile dysfunction: zero cases
• Loss of penile sensation: zero cases

The UroFill™ technique retrospective study of 300 men reinforced these findings: 91% reported being “completely” or “mostly” satisfied, with mean filler retention of 90% at 12 months. Eight localized skin infections occurred, all resolved with antibiotics. No filler removal was required.

A 230-patient Chinese cohort study documented a 4.3% overall complication rate (subcutaneous bleeding, nodules, infection), with no systemic or local allergic reactions. All complications resolved with conservative management, and no severe sequelae occurred.

The most common non-hypersensitivity complications of HA penile augmentation include filler migration, subcutaneous nodules (~2.2%), self-limited subcutaneous bleeding (~1.3%), and infection (~1%)—all manageable without surgical intervention.

The key safety advantage: zero operating room interventions were required for HA filler complications in the AUA dataset. Complications are managed conservatively in an office setting.

HA Technical Safety Considerations

Anatomical precision is non-negotiable. Injection must be placed between Buck’s fascia and the dartos fascia, while the superficial and deep dorsal veins, dorsal neurovascular bundle, and urethra must all be avoided.

Cross-linking density matters clinically: higher cross-linking increases filler viscosity and longevity but also increases risk of local inflammation, edema, and granuloma formation. Manufacturing quality also plays a role—industrial processes can introduce impurities that trigger hypersensitivity reactions.

Risk factors for infection post-HA injection include immunosuppression, uncontrolled type 2 diabetes, premature sexual intercourse post-procedure, and non-compliance with post-treatment protocols.

The literature consistently supports that outcomes are significantly better when procedures are performed by trained urologists or physicians using standardized, low-volume protocols. A staged treatment approach—incremental sessions allowing assessment of tissue response before additional volume—further reduces risk.

Polylactic Acid (PLA) Filler: Safety Profile of the Semi-Permanent Biostimulator

Polylactic acid occupies Tier 2 on the reversibility spectrum—semi-permanent and not reversible with any pharmacological agent. FDA-approved as Sculptra® for facial volume loss and HIV-associated lipoatrophy, its use for PGE is off-label.

PLA’s mechanism differs fundamentally from HA: it works by biostimulating fibroblast proliferation and neo-collagenesis. The body produces its own collagen around the PLA particles, creating delayed and extended results. This biostimulatory mechanism is both PLA’s clinical advantage (longer-lasting results) and its primary safety liability (the foreign body response can drive granuloma formation).

PLA vs. HA: Head-to-Head Safety and Efficacy Data

A 2022 multi-center RCT found no serious adverse events in either HA or PLA groups, with mean girth increases of 22.74 mm (HA) versus 20.23 mm (PLA) at 24 weeks. Satisfaction increased significantly in both groups.

A 2023 PRISMA-compliant systematic review and meta-analysis of 4 RCTs (n=283) found no statistically significant difference in complication incidence between HA and PLA (OR 0.98, 95% CI: 2.80–3.50; P=0.98). Both were considered safe and effective up to 18 months.

Critical caveat: “No statistically significant difference in complication incidence” does not mean “equal safety.” It means similar rates of minor complications—but the nature and reversibility of those complications differ fundamentally.

Published case series document three patients developing granulomatous reactions at least two months post-PLA injection, with two of three requiring surgical removal. Histology confirmed chronic granulomatous inflammation. When a PLA granuloma forms, there is no pharmacological dissolution option—management ranges from corticosteroid injection to surgical excision.

PMMA (Polymethylmethacrylate) Filler: Safety Profile of the Permanent Option

PMMA occupies Tier 3 on the reversibility spectrum—permanent, non-resorbable, and not reversible by any means short of surgical excision. Bellafill® is the only FDA-approved PMMA-based filler in the US, approved for nasolabial folds and acne scars. Its use for PGE is off-label.

PMMA consists of microspheres of polymethylmethacrylate suspended in a bovine collagen carrier. The collagen carrier is absorbed over time, but the PMMA microspheres remain permanently in tissue. Any complication that develops is also permanent unless surgically addressed.

PMMA Adverse Event Data: What the 587-Report Review Reveals

An integrative review of 587 PMMA complication reports covering 2004–2024 documented the most frequent delayed complication as granulomatous formations at 21%—more than 30 times the HA granuloma rate from the AUA 2024 data (0.63%).

Severe complications documented in the PMMA literature include septic shock and chronic renal failure—a categorically different severity level from anything documented with HA.

A 2025 prospective study found that PMMA showed greater augmentative effect than HA or PLA but lower patient satisfaction increase. Larger size gains did not translate to higher satisfaction.

Recovery differentials are significant. Stoller Medical Group’s clinical experience reflects the literature: HA-based approaches allow return to activity in approximately 10 days versus 40 or more days with permanent fillers such as PMMA.

The surgical removal problem compounds PMMA’s risk profile. Granulomas and complications often require surgical excision, which in the penile context carries significant risks including scarring, altered sensation, and functional compromise.

Tier 4: Unapproved and Illegal Substances — The Catastrophic End of the Spectrum

This tier represents a categorically different risk level—not a higher-risk version of approved options, but a class of substances associated with irreversible destruction and death.

Liquid injectable silicone (LIS) is not FDA-approved for any soft tissue augmentation. It is associated with migration throughout the body, chronic immune reactions, lymphatic obstruction, tissue necrosis, and permanent damage. Published case reports document penile amputation and death from underground silicone injection.

Other documented self-injection substances—mineral oil, paraffin, petroleum jelly, cod liver oil, metallic mercury, methamphetamine—are all associated with catastrophic, often irreversible complications including penile destruction and systemic toxicity.

Autologous fat transfer, while not illegal, carries risks of fat embolism (including one documented fatal case), reabsorption of 20–80% of fat cells within the first year, and complications including edema, hematoma, necrosis, and infection. For a detailed comparison of these approaches, see our analysis of penile filler vs. fat grafting.

Side-by-Side Safety Comparison: HA vs. PLA vs. PMMA

The key clinical takeaway: the reversibility spectrum predicts not just whether complications occur, but whether they can be corrected.

The Provider Qualification Factor: Why Material Safety Data Alone Is Insufficient

Even the safest material (HA) can produce catastrophic outcomes in the wrong hands. The dorsal neurovascular bundle, superficial and deep dorsal veins, and urethra are all within millimeters of the correct injection plane.

The literature consistently shows that outcomes are significantly better when procedures are performed by trained urologists or physicians with specific male anatomy expertise using standardized protocols.

Institutional safety markers to evaluate include: hospital-grade sterility protocols, medical-grade injectable materials with transparent safety data, staged treatment protocols, and mandatory psychological screening.

The 15,000+ procedure volume at Stoller Medical Group represents a meaningful safety signal. High-volume, specialized providers accumulate pattern recognition and complication management experience that low-volume providers cannot replicate.

Red flags indicating elevated risk regardless of material: non-physician providers, no psychological screening, single-session dramatic volume claims, inability to provide specific adverse event data, no hyaluronidase available on-site for HA procedures, and no clear complication management protocol. Men evaluating providers should review our guide on questions to ask at a penis enlargement medical consultation before their appointment.

Conclusion: The Clinically Defensible Choice at the Safest End of the Spectrum

The most important safety variable in penile girth enhancement is not just whether complications occur, but whether they can be corrected—and that depends entirely on the material used.

The key data points defining HA’s safety advantage are clear: 0.42% infection rate, 0.63% granuloma rate, zero erectile dysfunction, zero penile sensation loss, zero operating room interventions required. These figures contrast sharply with PMMA’s 21% granuloma rate and documented severe complications including septic shock and chronic renal failure.

All PGE filler use is off-label. Long-term data beyond 18 months is limited for all materials. The AUA and SMSNA both classify PGE as experimental pending further evidence.

The risk-adjusted analysis strongly favors the fully reversible option. The potential upside of marginally longer duration with PMMA does not justify the 21% granuloma rate and permanent complication risk.

Evidence-based decision-making in this field means choosing the material with the strongest safety data, the clearest reversibility mechanism, and the most experienced provider.

Schedule a Consultation with Stoller Medical Group

Stoller Medical Group offers consultations at five locations across New York, Pennsylvania, and Minnesota for men who have completed their research and are ready to move forward with an evidence-based approach.

The practice’s approach aligns with the safety framework established throughout this article: HA-based procedures at the safest end of the reversibility spectrum, 15,000+ procedures performed, board-certified physician leadership, and a 10-day recovery timeline.

The free consultation is where psychological screening, individualized anatomy assessment, and realistic goal-setting occur—the same process the SMSNA recommends. Consultations are confidential, reflecting an understanding of the sensitive nature of this decision.

Prospective patients are encouraged to bring their questions, their research, and their skepticism. A provider confident in their safety data welcomes informed patients.